Bio-Techne Statistics
Total Valuation
Bio-Techne has a market cap or net worth of $11.26 billion. The enterprise value is $11.29 billion.
| Market Cap | 11.26B |
| Enterprise Value | 11.29B |
Important Dates
The last earnings date was Wednesday, August 12, 2026, before market open.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | Aug 24, 2026 |
Share Statistics
Bio-Techne has 155.83 million shares outstanding. The number of shares has decreased by -1.70% in one year.
| Current Share Class | 155.83M |
| Shares Outstanding | 155.83M |
| Shares Change (YoY) | -1.70% |
| Shares Change (QoQ) | -0.24% |
| Owned by Insiders (%) | 0.33% |
| Owned by Institutions (%) | 114.80% |
| Float | 155.18M |
Valuation Ratios
The trailing PE ratio is 62.31 and the forward PE ratio is 35.47. Bio-Techne's PEG ratio is 7.44.
| PE Ratio | 62.31 |
| Forward PE | 35.47 |
| PS Ratio | 9.27 |
| Forward PS | 8.93 |
| PB Ratio | 5.35 |
| P/TBV Ratio | 13.58 |
| P/FCF Ratio | 42.79 |
| P/OCF Ratio | 38.56 |
| PEG Ratio | 7.44 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 31.79, with an EV/FCF ratio of 42.88.
| EV / Earnings | 62.07 |
| EV / Sales | 9.29 |
| EV / EBITDA | 31.79 |
| EV / EBIT | 43.80 |
| EV / FCF | 42.88 |
Financial Position
The company has a current ratio of 4.55, with a Debt / Equity ratio of 0.14.
| Current Ratio | 4.55 |
| Quick Ratio | 2.94 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 0.76 |
| Debt / FCF | 1.10 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 9.03% and return on invested capital (ROIC) is 9.07%.
| Return on Equity (ROE) | 9.03% |
| Return on Assets (ROA) | 6.26% |
| Return on Invested Capital (ROIC) | 9.07% |
| Return on Capital Employed (ROCE) | 10.64% |
| Weighted Average Cost of Capital (WACC) | 10.99% |
| Revenue Per Employee | $391,948 |
| Profits Per Employee | $58,665 |
| Employee Count | 3,100 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 2.13 |
Taxes
In the past 12 months, Bio-Techne has paid $58.82 million in taxes.
| Income Tax | 58.82M |
| Effective Tax Rate | 24.44% |
Stock Price Statistics
The stock price has increased by +31.73% in the last 52 weeks. The beta is 1.28, so Bio-Techne's price volatility has been higher than the market average.
| Beta (5Y) | 1.28 |
| 52-Week Price Change | +31.73% |
| 50-Day Moving Average | 68.47 |
| 200-Day Moving Average | 60.30 |
| Relative Strength Index (RSI) | 67.35 |
| Average Volume (20 Days) | 3,501,932 |
Short Selling Information
The latest short interest is 9.28 million, so 5.95% of the outstanding shares have been sold short.
| Short Interest | 9.28M |
| Short Previous Month | 12.12M |
| Short % of Shares Out | 5.95% |
| Short % of Float | 5.98% |
| Short Ratio (days to cover) | 1.80 |
Income Statement
In the last 12 months, Bio-Techne had revenue of $1.22 billion and earned $181.86 million in profits. Earnings per share was $1.16.
| Revenue | 1.22B |
| Gross Profit | 804.88M |
| Operating Income | 257.70M |
| Pretax Income | 240.68M |
| Net Income | 181.86M |
| EBITDA | 355.05M |
| EBIT | 257.70M |
| Earnings Per Share (EPS) | $1.16 |
Balance Sheet
The company has $264.71 million in cash and $289.09 million in debt, with a net cash position of -$24.38 million or -$0.16 per share.
| Cash & Cash Equivalents | 264.71M |
| Total Debt | 289.09M |
| Net Cash | -24.38M |
| Net Cash Per Share | -$0.16 |
| Equity (Book Value) | 2.11B |
| Book Value Per Share | 13.51 |
| Working Capital | 580.70M |
Cash Flow
In the last 12 months, operating cash flow was $292.07 million and capital expenditures -$28.85 million, giving a free cash flow of $263.22 million.
| Operating Cash Flow | 292.07M |
| Capital Expenditures | -28.85M |
| Depreciation & Amortization | 97.36M |
| Net Borrowing | -146.00M |
| Free Cash Flow | 263.22M |
| FCF Per Share | $1.69 |
Margins
Gross margin is 66.24%, with operating and profit margins of 21.21% and 14.97%.
| Gross Margin | 66.24% |
| Operating Margin | 21.21% |
| Pretax Margin | 19.81% |
| Profit Margin | 14.97% |
| EBITDA Margin | 29.22% |
| EBIT Margin | 21.21% |
| FCF Margin | 21.66% |
Dividends & Yields
This stock pays an annual dividend of $0.32, which amounts to a dividend yield of 0.44%.
| Dividend Per Share | $0.32 |
| Dividend Yield | 0.44% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 27.59% |
| Buyback Yield | 1.70% |
| Shareholder Yield | 2.14% |
| Earnings Yield | 1.61% |
| FCF Yield | 2.34% |
Analyst Forecast
The average price target for Bio-Techne is $70.73, which is -2.14% lower than the current price. The consensus rating is "Hold".
| Price Target | $70.73 |
| Price Target Difference | -2.14% |
| Analyst Consensus | Hold |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 8.24% |
| EPS Growth Forecast (3Y) | 10.16% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 30, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Nov 30, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 7 |